Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boundless Bio Inc (NQ: BOLD )

3.500 +0.180 (+5.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,657
Open 3.400
Bid (Size) 3.360 (1)
Ask (Size) 5.500 (1)
Prev. Close 3.320
Today's Range 3.245 - 3.570
52wk Range 2.820 - 14.72
Shares Outstanding 45,783,265
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire

Performance

YTD
-75.44%
-75.44%
1 Month
+20.69%
+20.69%
3 Month
+14.01%
+14.01%
6 Month
-59.25%
-59.25%
1 Year
-75.44%
-75.44%

More News

Read More
Boundless Bio Announces Departure of Chief Financial Officer
From Boundless Bio, Inc.
Via GlobeNewswire
BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024
Via InvestorPlace
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
Via InvestorPlace
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Boundless Bio
Via Business Wire
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
From Boundless Bio
Via Business Wire
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
From Boundless Bio
Via Business Wire
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
From Boundless Bio
Via Business Wire
Bayer-Backed Boundless Bio Falls After IPO
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.